Fluvoxamine
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Fluvoxamine: Paranoid personality disorder
One-Sentence Summary
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that is currently marketed in Australia. The TxGNN model predicts it may be effective for paranoid personality disorder. No clinical trials support this prediction, and only 2 publications were retrieved, neither of which tests fluvoxamine in this condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Paranoid personality disorder |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this report. Based on known information, fluvoxamine is an SSRI, a class that increases serotonin signalling in the brain. Mechanistically, serotonergic modulation might influence some traits seen in personality disorders, such as suspiciousness, anxiety and rigid thinking.
This link is speculative. The two retrieved papers concern body dysmorphic disorder with personality traits and the psychiatric effects of alpha-interferon. Neither tests fluvoxamine in paranoid personality disorder. The very high TxGNN score is a computational prediction and does not show that the drug works in this condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10929788 | 2000 | Cohort | Comprehensive Psychiatry | Assessed personality disorders and traits in 148 people with body dysmorphic disorder. Twenty-six took part in a fluvoxamine treatment study. It describes personality comorbidity and does not test fluvoxamine for paranoid personality disorder. |
| 11686052 | 2001 | Review | L’Encephale | Review of psychiatric complications of alpha-interferon, including personality, mood and psychotic symptoms. It provides no evidence on fluvoxamine treatment. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 14314J | Luvox | Tablet containing fluvoxamine maleate 100 mg (oral) | Not available in the data compiled for this report |
The licence is a valid single-ingredient product, and the oral tablet is the only dosage form recorded.
Safety Considerations
- Drug Interactions: The interaction check was completed and returned 100 potential interactions. Major-level interactions include alosetron, diethylpropion, dolasetron and bupropion. Moderate-level interactions include rabeprazole, aspirin, clarithromycin, morphine, pioglitazone, aprepitant and several corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone).
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. No clinical trial exists, and no retrieved publication studies fluvoxamine in paranoid personality disorder. The evidence is therefore at level L5.
To proceed, the following is needed:
- Controlled clinical studies of fluvoxamine in paranoid personality disorder
- Detailed mechanism of action data to support a plausible biological link
- A review of the TGA-approved Product Information for warnings and contraindications
- A drug interaction management plan, given the high number of recorded interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.